Market Research Logo

Fabry Disease - Pipeline Review, H2 2015

Fabry Disease - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Fabry Disease - Pipeline Review, H2 2015’, provides an overview of the Fabry Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fabry Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fabry Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fabry Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fabry Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fabry Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Fabry Disease Overview
Therapeutics Development
Pipeline Products for Fabry Disease - Overview
Pipeline Products for Fabry Disease - Comparative Analysis
Fabry Disease - Therapeutics under Development by Companies
Fabry Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fabry Disease - Products under Development by Companies
Fabry Disease - Companies Involved in Therapeutics Development
Actelion Ltd
Alexion Pharmaceuticals, Inc.
Amicus Therapeutics, Inc.
Biosidus S.A.
Genzyme Corporation
greenovation Biotech GmbH
iBio, Inc.
ISU ABXIS Co.,Ltd.
JCR Pharmaceuticals Co., Ltd.
Neuraltus Pharmaceuticals, Inc.
Pharming Group N.V.
Protalix BioTherapeutics, Inc.
Fabry Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(migalastat hydrochloride + agalsidase alfa) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
agalsidase alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
agalsidase beta biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
agalsidase beta biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genz-682452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402671 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lucerastat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
migalastat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
migalastat hydrochloride + Enzyme Replacement Therapy Biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOSS-AGAL - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry’s Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzymes for Pompe, Fabry and Hunter Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabry Disease - Recent Pipeline Updates
Fabry Disease - Dormant Projects
Fabry Disease - Product Development Milestones
Featured News & Press Releases
Jun 25, 2015: Amicus Therapeutics Announces Galafold Marketing Authorization Application Validated by European Medicines Agency
Jun 03, 2015: Amicus Therapeutics Submits Marketing Authorization Application for Full Approval of Fabry Monotherapy Galafold (Migalastat) in European Union
May 26, 2015: Amicus Therapeutics Fabry Monotherapy Granted Accelerated Assessment by European Regulators
May 26, 2015: Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators
Apr 28, 2015: Sanofi: FDA Grants Fast Track Designation To Genzyme's Investigational Substrate Reduction Therapy For The Treatment Of Fabry Disease
Apr 21, 2015: Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
Mar 09, 2015: Greenovation Successfully Completes Preclinical Toxicology Studies Of Alpha–Galactosidase
Feb 10, 2015: Amicus Therapeutics Announces Additional Positive Phase 3 Fabry Data on Patient Reported Outcomes at WORLD Symposium 2015
Jan 26, 2015: Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium
Jan 08, 2015: Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Fabry Disease, H2 2015
Number of Products under Development for Fabry Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Fabry Disease - Pipeline by Actelion Ltd, H2 2015
Fabry Disease - Pipeline by Alexion Pharmaceuticals, Inc., H2 2015
Fabry Disease - Pipeline by Amicus Therapeutics, Inc., H2 2015
Fabry Disease - Pipeline by Biosidus S.A., H2 2015
Fabry Disease - Pipeline by Genzyme Corporation, H2 2015
Fabry Disease - Pipeline by greenovation Biotech GmbH, H2 2015
Fabry Disease - Pipeline by iBio, Inc., H2 2015
Fabry Disease - Pipeline by ISU ABXIS Co.,Ltd., H2 2015
Fabry Disease - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
Fabry Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015
Fabry Disease - Pipeline by Pharming Group N.V., H2 2015
Fabry Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Fabry Disease Therapeutics - Recent Pipeline Updates, H2 2015
Fabry Disease - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Fabry Disease, H2 2015
Number of Products under Development for Fabry Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report